Our lab is conducting brain imaging research studies investigating people's behavior. We are looking for people between the ages of 18 and 65 to be study participants. As a schizophrenia study participant, you will be asked to complete a set of self-report questionnaires probing personality traits. You will also complete a number of computer-based…
In this study, we are trying to learn more about the symptoms of psychosis, specifically to learn how alterations in the brain may produce certain experiences (including voice hearing or auditory hallucinations) that are common in people with psychosis or schizophrenia. The study involves clinical interviews, computer tests, and magnetic resonance imaging (…
This study is for individuals who have Cushings disease and want to join voluntarily in this study to find out if a study drug called osilodrostat (LCI699) is safe and has beneficial effects in people who have Cushings disease. Cushings disease is a rare but debilitating disease. Cushings disease is caused by a benign tumor of the pituitary gland. The tumor…
The purpose of this study is to determine if measuring blood levels of proteins called POMC, AgRP, and chromogrannin A (CGA) can be used to diagnose and track tumor growth and recurrence in patients that have ACTH-dependent Cushing's syndrome, non-secreting pituitary tumors, and other neuroendocrine tumors. We invite you to participate if you have: a…
The experimental drug being investigated in this study is called rucaparib. Rucaparib is being developed by Clovis Oncology, Inc. (the Sponsor), a biopharmaceutical company with headquarters in the United States (US). Rucaparib (trade name: Rubraca) is a medicine that is approved in the European Union (EU) and the US for use in certain types of ovarian…
Our lab is conducting a series of research studies that investigate how specific brain regions are related to functioning in work, school, and in other social situations. As a study participant, you will be asked to complete clinical and neuropsychological assessments, an eye-tracking task, and a non-invasive MRI scan. Study participants earn between $15-50…
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
The purpose of this study is to confirm the effectiveness and safety of LCI699 in treating patients with Cushing's disease. Patients will be treated with the invesitigational drug LCI699 at doses up to 60 mg a day, and possibly for a short period of time with placebo. A placebo is a dummy drug ("pill") with no active medicine inside.
This study plans to learn more about an investigational new drug called lumateperone tosylate (ITI-007) and may help us find new types of treatment for schizophrenia and schizoaffective disorder.
The purpose of this study is to determine whether the brain wave patterns are improved after administration of CVN058 compared to placebo in subjects with schizophrenia. The study uses electroencephalography (EEG) to measure naturally occurring brain waves as you listen to recorded sounds.
SY-1365 is an investigational drug that stops the function of a protein known as CDK7. Previous workhas shown that CDK7 is necessary for some cancers to grow. Therefore, SY-1365 could be used to slow down the growth of cancer. This research study is being done to understand the highest tolerated dose of SY-1365, and to assess the safety of SY-1365 in…
The purpose of this study is to evaluate the efficacy, safety and tolerability of different doses and durations of TV-46000 given by subcutaneous (under the skin) injection as compared to placebo for use as a potential maintenance in adults with schizophrenia.
This is a Phase 1/2 multicenter study of VX15/2503 in pediatric patients and young adults with solid tumors which have come back or have not responded to standard therapy. The study treatment is considered experimental because VX15/2503 is not approved by the United States (US) Food and drug Administration (FDA) for treating pediatric patients and young…
In this study, we are trying to learn more about the symptoms of schizophrenia, specifically to learn how abnormalities in the brain may produce certain experiences that are common in patients with schizophrenia. The study involves clinical interviews, clinical chart review, computer tests, and magnetic resonance imaging (MRI) scans.